NEW YORK (GenomeWeb) – Bionano Genomics on Wednesday lowered the size of its proposed IPO, according to a filing with the US Securities and Exchange Commission.
The San Diego-based genomic research tools company plans to offer 2,450,000 units, each consisting of one share of common stock and one warrant to purchase a share of common stock, at a price of $6.00 to $7.00 per unit.
At the midpoint of the range, the company would raise about $16 million. In July BioNano had filed with the SEC to offer 5.5 million shares of stock for between $5 and $6 for a proposed maximum offering of about $38 million. And in its preliminary prospectus filed with the SEC in June the company said it was targeting $34.5 million.
The company's stock has been approved for listing on the Nasdaq under the symbol BNGO, and BioNano has applied for the listing of the units and the warrants on Nasdaq under the symbols BNGOU and BNGOW, respectively. The warrants and shares will trade together as units only during the first 30 days following the prospectus date, and thereafter will automatically separate and trade separately unless Roth Capital Partners, as the representative of the underwriters, determines that an earlier date is acceptable.
Bionano sells a DNA mapping system for structural variation detection called Saphyr that it launched commercially in 2017. The underlying optical mapping technology involves nanochannels that hold single DNA molecules. The company said it has an installed base of more than 90 systems, including both the Saphyr and its predecessor Irys.